UNIVERSITY OF NORTH CAROLINA HOSPITALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1989-01-01

Employees: -

Market Cap: -

Website: http://www.unc.edu/interactive-tour/unc-hospitals/

Clinical Trials

De-intensification of Radiation & Chemotherapy in Low-Risk Human Papillomavirus-related Oropharyngeal Squamous Cell Ca

Phase 2

Completed

Conditions: Carcinoma, Squamous Cell
Head and Neck Neoplasms
Oropharyngeal Neoplasms

Interventions: Radiation: Intensity Modulated Radiotherapy (IMRT)
Drug: Cisplatin
Procedure: Limited surgical evaluation

First Posted Date: 2012-02-10

Last Posted Date: 2024-11-13

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT01530997

Locations: 🇺🇸
University of Florida, Department of Radiation Oncology, Gainesville, Florida, United States
🇺🇸
Penrose Cancer Center, Colorado Springs, Colorado, United States
🇺🇸
Rex Healthcare, Raleigh, North Carolina, United States

and more 2 locations

Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: Vorinostat
Drug: Bortezomib
Drug: pegylated liposomal doxorubicin

First Posted Date: 2011-12-15

Last Posted Date: 2012-05-11

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Registration Number: NCT01492881

Locations: 🇺🇸
Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Patient Preferences for Breast Reconstruction After Mastectomy

Completed

Conditions: Breast Cancer

First Posted Date: 2011-12-08

Last Posted Date: 2017-04-26

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 145

Registration Number: NCT01488357

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Advanced Adult Hepatocellular Carcinoma

Interventions: Drug: Everolimus
Drug: Pasireotide

First Posted Date: 2011-12-08

Last Posted Date: 2016-04-07

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 24

Registration Number: NCT01488487

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
🇺🇸
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Development of a Tumor Molecular Analyses Program and Its Use to Support Treatment Decisions

Not Applicable

Completed

Conditions: Neoplasm

Interventions: Diagnostic Test: Tumor Genetic Sequencing

First Posted Date: 2011-10-21

Last Posted Date: 2019-12-30

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 2798

Registration Number: NCT01457196

Locations: 🇺🇸
University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Phase 2

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Pazopanib

First Posted Date: 2011-05-26

Last Posted Date: 2018-04-25

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 21

Registration Number: NCT01361113

Locations: 🇺🇸
North Carolina Cancer Hospital (UNC), Chapel Hill, North Carolina, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Bavituximab

First Posted Date: 2011-03-25

Last Posted Date: 2018-12-04

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT01323062

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States

A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Phase 2

Completed

Conditions: HER-2 Positive Breast Cancer

Interventions: Drug: Everolimus
Drug: Vinorelbine
Drug: Trastuzumab

First Posted Date: 2011-03-01

Last Posted Date: 2018-12-17

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 32

Registration Number: NCT01305941

Locations: 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸
Carolinas Healthcare System, Charlotte, North Carolina, United States
🇺🇸
University Of Alabama at Birmingham, Birmingham, Alabama, United States

and more 1 locations

Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients

Active, not recruiting

Conditions: Breast Cancer

First Posted Date: 2011-03-01

Last Posted Date: 2023-11-28

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 100

Registration Number: NCT01305954

Locations: 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Placebo
Drug: Regorafenib (BAY 73-4506)
Drug: FOLFIRI

First Posted Date: 2011-02-17

Last Posted Date: 2021-01-06

Lead Sponsor: UNC Lineberger Comprehensive Cancer Center

Target Recruit Count: 181

Registration Number: NCT01298570

Locations: 🇺🇸
Portsmouth Naval Medical Center, Portsmouth, Virginia, United States
🇺🇸
Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸
University of Virginia, Charlottesville, Virginia, United States

and more 21 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy